While your journey may look different than others, you can still forge your own path with advocacy, columnist Marisa Zeppieri ...

Excessive production of type I interferon (IFN-I) — a molecule that mediates immune and inflammatory responses — in people with systemic lupus erythematosus (SLE) may be caused by small fragments of ...

Despite what you’ve read, there is no established diet for lupus. There are certain foods that may improve life while living with lupus, and that are certain foods that can worsen your flares and how ...

PALIZADE, a Phase 2b clinical trial of Kezar Life Sciences’ investigational therapy zetomipzomib, is still enrolling systemic lupus erythematosus (SLE) patients with active lupus nephritis, a severe ...

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

Hemogenyx Pharmaceuticals and Rockefeller University recently agreed to collaborate on developing new treatments for lupus using the biotechnology company’s humanized mouse models. Hemogenyx, which is ...

Children born to mothers with lupus may end up with developmental disabilities, according to a review of more than two dozen studies. Learning and reading difficulties and dyslexia are among the ...

Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to RemeGen‘s RC18 (telitacicept) to treat people with systemic lupus erythematosus (SLE). A therapy candidate is put on ...

A single infusion of mesenchymal stem cells (MSCs) — those that make cells of the cartilage, bone, and fat — decreased the number of auto-reactive immune cells in difficult-to-treat systemic lupus ...

Adding RC18 (telitacicept) to standard therapy significantly lowered disease activity in systemic lupus erythematosus (SLE) patients in a Phase 2b trial, data show. The treatment was also ...